MIRA INFORM REPORT

 

 

Report Date :

20.02.2012

 

IDENTIFICATION DETAILS

 

Name :

BIOFAC AS

 

 

Registered Office :

Englandsvej 350-356 Kastrup, 2770

 

 

Country :

Denmark

 

 

Financials (as on) :

30.06.2011

 

 

Year of Establishment :

1956

 

 

Com. Reg. No.:

62550511

 

 

Legal Form :

Private Subsidiary

 

 

Line of Business :

Manufacture of pharmaceutical preparations

 

 

No. of Employees :

130

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Denmark

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name and address

 

Top of Form

Biofac A/S

                                                                                                                                               

 

Englandsvej 350-356

 

 

Kastrup, 2770

Denmark

 

Tel:

+45 70 10 30 20

Fax:

+45 32 50 16 05

 

Suggest Company URL

 

Employees:

130

Company Type:

Private Subsidiary

Corporate Family:

2 Companies

Ultimate Parent:

ZERIA PHARMACEUTICAL CO., LTD.

 

 

Incorporation Date:

1956

Financials in:

USD (mil)

 

 

Fiscal Year End:

30-Jun-2011

Reporting Currency:

Danish Krone

Annual Sales:

31.8

Net Income:

(3.1)

Total Assets:

80.8

                                      

Business Description       

 

Biofac A/S is primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

          

Industry                                                                                                                               

 

Industry

Biotechnology and Drugs

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

NACE 2002:

2442 - Manufacture of pharmaceutical preparations

NAICS 2002:

325412 - Pharmaceutical Preparation Manufacturing

UK SIC 2003:

24421 - Manufacture of medicaments

US SIC 1987:

2834 - Pharmaceutical Preparations

                      

Key Executives           

   

 

Name

Title

Peter RΓΈrvig

Managing Director / Director, Purchasing Executive

Kim Almfort

Finance Manager

Helle RΓΈrvig

Sales Director, Board Member

Claus S. Albrechtsen

Production Director

Svend Blankholm

Board Member


Corporate Overview

 

Location
Englandsvej 350-356
Kastrup, 2770
Denmark

 

Tel:

+45 70 10 30 20

Fax:

+45 32 50 16 05

 

Suggest Company URL

Sales DKK(mil):

31.8

Assets DKK(mil):

80.8

Employees:

130

Fiscal Year End:

30-Jun-2011

 

Industry:

Biotechnology and Drugs

Incorporation Date:

1956

Company Type:

Private Subsidiary

Quoted Status:

Not Quoted

Registered No.(DNK):

62550511

 

Managing Director / Director, Purchasing Executive:

Peter RΓΈrvig

Contents

Industry Codes

Business Description

Financial Data

Key Corporate Relationships

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

 

NACE 2002 Codes:

2442

-

Manufacture of pharmaceutical preparations

2441

-

Manufacture of basic pharmaceutical products

 

NAICS 2002 Codes:

325412

-

Pharmaceutical Preparation Manufacturing

325411

-

Medicinal and Botanical Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

2833

-

Medicinal Chemicals and Botanical Products

 

UK SIC 2003:

2441

-

Manufacture of basic pharmaceutical products

24421

-

Manufacture of medicaments

 

 

Business Description

Biofac A/S is primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

 

 

 

 

 

 

 

 

Financial Data

 

Financials in:

DKK(mil)

 

Revenue:

31.8

Net Income:

-3.1

Assets:

80.8

Total Liabilities:

0.0

 

 

 

Date of Financial Data:

30-Jun-2011

 

1 Year Growth

NA

NA

NA

 

 

Key Corporate Relationships

Bank:

Giro Account 9088016

 

 

 

 

 

 

 

 

 

 

 

Corporate Structure News

Biofac A/S
Total Corporate Family Members: 2

 

 

 

 

Company Name

Company Type

Location

Country

Industry

Sales
( mil)

Employees

ZERIA PHARMACEUTICAL CO., LTD.

Parent

Chuo-ku

Japan

Biotechnology and Drugs

49,482.2

1,287

Biofac A/S

Subsidiary

Kastrup

Denmark

Biotechnology and Drugs

31.8

130

 

 

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

Svend Blankholm

 

Board Member

Director/Board Member

Helle RΓΈrvig

 

Sales Director, Board Member

Director/Board Member

Peter RΓΈrvig

 

Managing Director / Director, Purchasing Executive

Director/Board Member

Niels Ulrik Heine

 

Board Member

Director/Board Member

 

Executives

 

Name

Title

Function

Peter RΓΈrvig

 

Managing Director / Director, Purchasing Executive

Managing Director

Kim Almfort

 

Finance Manager

Finance Executive

Helle RΓΈrvig

 

Sales Director, Board Member

Sales Executive

Claus S. Albrechtsen

 

Production Director

Product Management Executive

 

 

 

Annual Profit & Loss

 

 

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

DKK

DKK

DKK

Exchange Rate (Period Average)

1

1

1

Consolidated

No

No

No

 

 

 

 

Total Revenue

31.8

27.8

153.1

Gross Profit

9.7

15.8

50.4

Operating Income

-3.8

2.7

1.1

Net Income

-3.1

1.1

-3.8

 

 

 

Annual Balance Sheet

Financials in: DKK (mil)

 

 

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

Filed Currency

DKK

DKK

DKK

Exchange Rate

1

1

1

Consolidated

No

No

No

 

 

 

 

Total Assets

80.8

95.9

160.6

Provisions

2.4

2.7

7.9

Total Liabilities

-

-

102.9

Total Equity

11.9

15.1

49.8

 

 

 

Annual Ratios

 

 

 

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

-

-

-

Exchange Rate

-

-

-

Consolidated

No

No

No

 

 

 

 

Operating Margin

-11.92

9.80

0.71

Current Ratio

105.47

109.50

109.91

Total debt/total equity

14.71

15.79

31.03

Return on average equity

-

7.02

-

 

 

 

Annual Growth Rates

 

 

 

 

 

 

30-Jun-2010

30-Jun-2009

Period Length

12 Months

12 Months

Filed Currency

-

-

Exchange Rate

-

-

Consolidated

No

No

 

 

 

Turnover Percent Change

14.34%

-81.82%

Marginal Contribution Percent Change

-38.70%

-68.56%

Operating Results Percent Change

-239.08%

151.20%

Profit/Loss for the Year Percent Change

-393.23%

128.33%

Assets Percent Change

-15.78%

-40.28%

Provisions Percent Change

-10.27%

-65.36%

Equity Capital Percent Change

-21.51%

-69.61%

Operating Margin Percent Change

-221.63%

1,280.28%

Current Ratio Percent Change

-3.68%

-0.37%

Debt/Equity Ratio Percent Change

-6.84%

-49.11%

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.49.21

UK Pound

1

Rs.77.75

Euro

1

Rs.64.58

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.